Fig. 4: Comparison of primary and metastatic ER-positive/HER2-negative breast cancer in elderly patients and spectrum of germline and somatic alterations in HRD/DDR genes in the whole cohort.
From: Genomic landscape of breast cancer in elderly patients
a Forest plots showing odds ratio (OR) of cancer genes altered at statistically significantly different rates between metastatic (n = 81) and primary (n = 179) ER+/HER2- breast cancer (BC) samples in elderly individuals. b Dominant mutational signatures in primary and metastatic ER+/HER2- BC in elderly patients. Boxplots depicting mutational signature exposures of aging (c) and APOBEC (d) signatures in primary and metastatic ER+/HER2- BC in elderly patients. Tumor mutation burden (TMB; e) and fraction of genome altered (FGA; f) or primary and metastatic ER+/HER2- BC. n.s., non-significant; *P < 0 .05, **P < 0.01, ***P < 0.001; Mann-Whitney U test and Fisher’s exact test.
